Bavarian Nordic A/S
BAVA
Rang in Aktien
#5096
Hellerup, Denmark-based Bavarian Nordic A/S, founded in 1992, specializes in... Hellerup, Denmark-based Bavarian Nordic A/S, founded in 1992, specializes in the research, production, and global distribution of vital, life-saving vaccines. The company's commercialized offerings include non-replicating vaccines for smallpox and monkeypox, marketed as IMVAMUNE, IMVANEX, and JYNNEOS. Additionally, their portfolio features Rabipur/RabAvert for rabies prevention, Encepur for tick-borne encephalitis, and MVABEA, an Ebola vaccine. Bavarian Nordic also maintains a robust pipeline of investigational treatments. This includes MVA-BN (freeze-dried), which has successfully completed Phase III clinical trials for smallpox; MVA-BN RSV, currently in Phase III development for respiratory syncytial virus; ABNCoV2, which completed Phase II trials targeting SARS-CoV-2; and TAEK-VAC, presently in Phase I/II trials for advanced HER2 and brachyury-expressing cancers. The firm engages in key partnerships, notably a license and collaboration agreement with AdaptVac, and licensing agreements with both the National Cancer Institute and the Public Health Service. Bavarian Nordic operates across a wide international footprint, with a presence in countries such as the United States, Germany, Belgium, France, Canada, the United Kingdom, Hong Kong, Saudi Arabia, Australia, Switzerland, and numerous other global markets.
Aktienkurs
$36.69
Zuletzt synchronisiert: 2026-10-21
Marktkapitalisierung
$2.79B
Veränderung (1 Tag)
-4.51%
Veränderung (1 Jahr)
-1.42%
Land
DK
Handel Bavarian Nordic A/S (BAVA)
Kategorie
Healthcare
Kursverlauf für Bavarian Nordic A/S (BAVA)
Höchster Schlusskurs: $33.55 am 2026-10-01
Niedrigster Schlusskurs: $34.65 am 2003-11-01
Niedrigster Schlusskurs: $34.65 am 2003-11-01
Kursverlauf der Aktie von Bavarian Nordic A/S von 2003 bis 2026
Jährliche Kursentwicklung
| Jahr | Leistung |
|---|---|
| 2026 (TTM) | 0.33% |
| 2025 | 10.57% |
| 2024 | 8.76% |
| 2023 | -19.61% |
| 2022 | -25.66% |
| 2021 | 40.00% |
| 2020 | 18.69% |
| 2019 | 29.14% |
| 2018 | -47.44% |
| 2017 | 12.36% |
| 2016 | -31.03% |
| 2015 | 60.26% |
| 2014 | 138.27% |
| 2013 | 42.61% |
| 2012 | 26.87% |
| 2011 | -82.59% |
| 2010 | 34.81% |
| 2009 | 16.54% |
| 2008 | -59.42% |
| 2007 | -31.66% |
| 2006 | -0.87% |
| 2005 | -1.44% |
| 2004 | 170.56% |
| 2003 | 0.00% |
Aktienkurs vergleichbarer Unternehmen oder Wettbewerber
| Unternehmen | Aktienkurs | Veränderung 1J% | Land |
|---|---|---|---|
| $527.18 | 23.62% |
US
|
|
| $251.29 | 835.90% |
US
|
|
| $137.50 | -4.01% |
AU
|
|
| $890.85 | 9.42% |
NL
|
|
| $752.87 | 7.01% |
CH
|
